CA2301000C - An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine - Google Patents

An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine Download PDF

Info

Publication number
CA2301000C
CA2301000C CA002301000A CA2301000A CA2301000C CA 2301000 C CA2301000 C CA 2301000C CA 002301000 A CA002301000 A CA 002301000A CA 2301000 A CA2301000 A CA 2301000A CA 2301000 C CA2301000 C CA 2301000C
Authority
CA
Canada
Prior art keywords
virus
vaccine
cell
japanese encephalitis
vero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002301000A
Other languages
English (en)
French (fr)
Other versions
CA2301000A1 (en
Inventor
Hyun Su Kim
Wang Don Yoo
Soo Ok Kim
Sung Hee Lee
Sang Bum Moon
Sun Pyo Hong
Yong Cheol Shin
Yong Ju Chung
Kenneth H. Eckels
Bruce Innis
Joseph R. Putnak
Leonard N. Binn
Ashok K. Srivastava
Doria R. Dubois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ Corp
United States Department of the Army
Original Assignee
CJ Corp
United States Department of the Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ Corp, United States Department of the Army filed Critical CJ Corp
Publication of CA2301000A1 publication Critical patent/CA2301000A1/en
Application granted granted Critical
Publication of CA2301000C publication Critical patent/CA2301000C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002301000A 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine Expired - Lifetime CA2301000C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR19970042002 1997-08-28
KR1997/42002 1997-08-28
KR19970042001 1997-08-28
KR1997/42001 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (2)

Publication Number Publication Date
CA2301000A1 CA2301000A1 (en) 1999-03-11
CA2301000C true CA2301000C (en) 2003-07-08

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002301000A Expired - Lifetime CA2301000C (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Country Status (15)

Country Link
US (1) US6309650B1 (enExample)
EP (2) EP1025209B1 (enExample)
JP (1) JP4161017B2 (enExample)
KR (1) KR100314404B1 (enExample)
CN (1) CN1142271C (enExample)
AU (1) AU748730B2 (enExample)
CA (1) CA2301000C (enExample)
DE (2) DE69837211T2 (enExample)
DK (2) DK1025209T3 (enExample)
ES (2) ES2382946T3 (enExample)
FR (1) FR09C0037I2 (enExample)
MY (1) MY129773A (enExample)
NL (1) NL300391I2 (enExample)
NZ (1) NZ503522A (enExample)
WO (1) WO1999011762A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
KR20010032699A (ko) * 1998-10-05 2001-04-25 무따이 마사히꼬 일본 뇌염 바이러스 감염에 대한 불활성 백신을 위한증강된 면역원 및 그 제조방법
MXPA01010681A (es) * 1999-04-22 2003-08-20 Us Agriculture Vacuna de sindrome respiratorio y reproductiva porcina a base de ja-142 aislado.
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
EP2117589A4 (en) * 2007-01-31 2010-07-21 Sanofi Pasteur Biologics Co FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS
CA2710611C (en) * 2007-12-26 2016-12-20 The Kitasato Institute Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
KR101507822B1 (ko) 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
CN102112151A (zh) * 2008-07-30 2011-06-29 久光制药株式会社 微针装置及由微针装置使日本脑炎病毒抗原的功效升高的方法
KR20120027381A (ko) * 2009-05-25 2012-03-21 파나세아 바이오테크 리미티드 일본뇌염 백신 및 그것의 제조 방법
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
EP3269386B1 (en) 2011-12-06 2022-09-14 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
WO2015059714A1 (en) * 2013-09-14 2015-04-30 Bharat Biotech International Limited Emergency mode in a hybrid vehicle
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
ES2973267T3 (es) * 2015-12-23 2024-06-19 Valneva Se Purificación de virus
CA3010049C (en) * 2016-01-15 2021-10-12 The Chemo-Sero-Therapeutic Research Institute Vaccine containing immobilized virus particles
JP7301811B2 (ja) 2017-09-21 2023-07-03 ヴァルネヴァ エスイー 免疫原性チクングニアウイルスｃｈｉｋｖ－ｄｅｌｔａ ５ｎｓｐ３を含む医薬組成物を製造する方法
KR20200117981A (ko) 2017-11-03 2020-10-14 다케다 백신즈 인코포레이티드 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들
MX2020005554A (es) 2017-11-30 2020-10-12 Takeda Vaccines Inc Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
CN110684747B (zh) 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
CN112601815B (zh) * 2018-08-27 2024-11-01 迈凯恩技术有限公司 使用永生化单核细胞和诱导细胞的抗感染药物、疫苗等的评价方法
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
JP2023515908A (ja) 2020-03-01 2023-04-14 ヴァルネヴァ・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ＣｐＧアジュバント化ＳＡＲＳ－ＣｏＶ－２ウイルスワクチン
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
AU2021232062A1 (en) 2020-03-06 2022-09-29 Colorado State University Research Foundation Production of vaccines comprising inactivated SARS-CoV-2 viral particles
UY39159A (es) 2020-04-06 2021-10-29 Valneva Austria Gmbh VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
EP4428231A4 (en) * 2022-04-20 2025-11-19 Korea Nat Institute Of Health GENOTYPE 5 OF HIGH-TIRES JAPANESE ENCEPHALITIS VIRUS AND ITS USE
EP4652265A1 (en) 2023-01-18 2025-11-26 Valneva Austria GmbH Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (en) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production

Also Published As

Publication number Publication date
NL300391I2 (nl) 2009-11-02
DK1604685T3 (da) 2012-06-18
DE122009000037I2 (de) 2011-06-16
EP1604685B1 (en) 2012-02-22
MY129773A (en) 2007-04-30
KR100314404B1 (ko) 2002-10-12
CA2301000A1 (en) 1999-03-11
DE122009000037I1 (de) 2009-11-05
WO1999011762A1 (en) 1999-03-11
NL300391I1 (nl) 2009-08-03
NZ503522A (en) 2001-06-29
KR19990023955A (ko) 1999-03-25
FR09C0037I1 (enExample) 2009-09-25
AU9004798A (en) 1999-03-22
CN1142271C (zh) 2004-03-17
JP4161017B2 (ja) 2008-10-08
DE69837211T2 (de) 2007-12-06
FR09C0037I2 (fr) 2021-11-05
AU748730B2 (en) 2002-06-13
EP1025209A1 (en) 2000-08-09
DK1025209T3 (da) 2007-06-25
DE69837211D1 (de) 2007-04-12
US6309650B1 (en) 2001-10-30
EP1604685A2 (en) 2005-12-14
ES2281929T3 (es) 2007-10-01
ES2382946T3 (es) 2012-06-14
EP1025209B1 (en) 2007-02-28
CN1272879A (zh) 2000-11-08
JP2001514844A (ja) 2001-09-18
EP1604685A3 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
CA2301000C (en) An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
KR102839410B1 (ko) 백신 조성물
US10548964B2 (en) Antigens and vaccines directed against human enteroviruses
CN107050445A (zh) 灭活登革热病毒疫苗
EP2459709B1 (en) High yield yellow fever virus strain with increased propagation in cells
KR20110132379A (ko) 알루미늄-비함유 아주반트를 포함하는 불활성화 뎅기 바이러스 백신
Putnak et al. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells
WO2012073257A2 (en) Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals
JP4371343B2 (ja) 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法
JPWO2000020565A1 (ja) 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法
KR20120027381A (ko) 일본뇌염 백신 및 그것의 제조 방법
TWI228147B (en) An attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
BR112018000862B1 (pt) Composição de vacina estável, método para produção de antígeno de vírus da zika recombinante e método para preparação de antígeno de virião (vírus) inteiro inativado da zika para formulação de vacina de vírus da zika

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180827